In patients with Hypophysitis, biochemical testing of the pituitary-adrenal axis may reveal secondary (central) adrenal insufficiency. This finding defines a specific clinical sub-population that requires a targeted treatment approach.
Secondary (central) adrenal insufficiency has been identified on biochemical testing of the pituitary-adrenal axis. This is the primary condition driving treatment selection in this scenario.
Management involves hydrocortisone replacement therapy. The complete dosing schedule, dose-adjustment guidance, and full clinical algorithm are available in the structured protocol.
DOI: 10.1016/j.beem.2019.101371
AI is treated with hydrocortisone 15 to 20 mg that is typically body-surface area based, and administered in two or more divided doses, with the highest dose to be taken in the morning after waking up.
View source ↗